- Molecular NameOxprenolol
- Synonym(+-)-oxprenolol; (+)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; (1)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; 1-(Isopropylamino)-2-hydroxy-3-(o-(allyloxy)phenoxy)propane; 1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)-2-propanol; 1-[2-(Allyloxy)phenoxy]-3-(isopropylamino)-2-propanol; DL-oxprenolol; Osprenololo [dcit]; Oxprenololum [inn-latin]
- Weight265.353
- Drugbank_IDDB01580
- ACS_NO6452-71-7
- Show 3D model
- LogP (experiment)2.18
- LogP (predicted, AB/LogP v2.0)2.01
- pka9.5
- LogD (pH=7, predicted)-0.39
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)0.58
- LogSw (predicted, AB/LogsW2.0)12.69
- Sw (mg/ml) (predicted, ACD/Labs)4.3
- No.of HBond Donors2
- No.of HBond Acceptors4
- No.of Rotatable Bonds9
- TPSA50.72
- StatusFDA approved
- AdministrationN/A
- PharmacologyA non-selective beta blocker with some intrinsic sympathomimetic activity. It is used for the treatment of angina pectoris and abnormal heart rhythms. It is also used for treating high blood pressure.
- Absorption_value95.0
- Absorption (description)N/A
- Caco_2-4.68
- Bioavailability44.0
- Protein binding80.0
- Volume of distribution (VD)1 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmOxprenolol is extensively metabolized in humans, including dealkylation, desamination, and aromatic hydroxylation, and more than 50% of the dose is excreted in the urine as the 0-glucuronide of the parent drug.
- Half life1~3 h
- ExcretionRenal Lactic (In lactiferous females)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A